Anzeige
❌
Mehr »
Donnerstag, 19.11.2026 - Börsentäglich über 12.000 News
Folge dem Geld: Methan im Fokus der COP31!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
NB

WKN: A3CTQ0 | ISIN: FR0014003XT0 | Ticker: 82F
Frankfurt
19.11.26 | 08:02
0,268 Euro
+1,13 % +0,003
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
NFL BIOSCIENCES SA Chart 1 Jahr
5-Tage-Chart
NFL BIOSCIENCES SA 5-Tage-Chart
RealtimeGeldBriefZeit
0,2940,41208:53

Aktuelle News zur NFL BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
08:06NFL Biosciences Issues Share Subscription Warrants and Grants Them Free of Charge to All Shareholders212The Transaction is structured in two stages: A Warrants: Each existing share entitles its holder to one A Warrant (BSA A), exercisable from November 24 to December 17, 2026. Three A Warrants...
► Artikel lesen
08:06NFL Biosciences Announces Enrollment of the First Participant in Its Phase 2 Tonic Study Evaluating NFL-102 for Smoking and Nicotine Cessation179Effective start of the clinical trial with the enrolment of the first participant in Part A, involving 40 smokers First clinical evaluation of NFL-102 in smokers wishing to quit Initial...
► Artikel lesen
FrNFL Biosciences Strengthens Its Intellectual Property With a New Patent Application for NFL-102326Regulatory News: NFL BIOSCIENCES (Euronext Growth Paris FR0014003XT0 ALNFL), a biopharmaceutical company developing immunotherapies for the treatment of tobacco dependence, announces the filing...
► Artikel lesen
30.10.NFL Biosciences will participate in the BIO-Europe 2026 conference to continue discussions with potential partners regarding NFL-101 and NFL-102321A strategic opportunity to advance ongoing discussions Regulatory News: NFL BIOSCIENCES (Euronext Growth Paris FR0014003XT0 ALNFL), a biopharmaceutical company developing immunotherapies for...
► Artikel lesen
NFL BIOSCIENCES Aktie jetzt für 0€ handeln
22.10.NFL Biosciences Reports Its 2026 Half-Year Results and Progress With Its Two Immunotherapies for Smoking and Nicotine Cessation527NFL-101 immunotherapy aimed at reducing neuroinflammation: Biomarker results supporting a personalized medicine approach Next step: discussions with the FDA and EMA to confirm...
► Artikel lesen
22.10.NFL Biosciences Receives Regulatory Approval to Begin Its Phase 2 TONIC Trial for Smoking and Nicotine Cessation561The TONIC Phase 2 trial evaluating NFL-102 consists of Part A (the first 40 participants) and Part B (the next 270 participants) Enrollment of the first participants (Part A) is scheduled...
► Artikel lesen
06.10.NFL Biosciences: Progress Update Ahead of Upcoming Value-Creating Milestones for Its Two Clinical Programs in Smoking Cessation372Regulatory News: NFL BIOSCIENCES (Euronext Growth Paris FR0014003XT0 ALNFL), a biopharmaceutical company developing immunotherapies for smoking and nicotine cessation, provides an update on progress...
► Artikel lesen
08.09.NFL Biosciences to Present Its Personalized Medicine Approach to Smoking Cessation at the 20th Congress of the Société Francophone de Tabacologie366Oral presentation selected by the SFT 2026 dedicated to the predictive biomarker associated with NFL-101 efficacy in smoking cessation Presentation of the results of a post-hoc analysis...
► Artikel lesen
28.07.NFL Biosciences submits phase 2 smoking cessation trial to regulators1
28.07.NFL Biosciences Submits an Application for Authorization of the Phase 2 TONIC Clinical Trial Evaluating NFL-102 in Smoking Cessation489A Phase 2 clinical trial involving 310 smokers, designed to confirm the safety profile of NFL-102, determine its optimal dose, and evaluate its efficacy An adaptive design that allows for...
► Artikel lesen
07.07.International Scientific Recognition for NFL Biosciences: 3 Presentations Selected at the 2026 SRNT-Europe Conference, Including an Oral Presentation on NFL-102687Strengthening the international scientific recognition of NFL Biosciences' tobacco franchise within the leading scientific community dedicated to nicotine and tobacco research Oral presentation...
► Artikel lesen
30.06.NFL Biosciences Announces the Successful Manufacturing of a GMP Clinical Batch of NFL-102 and Validates Its Industrial Production Chain454Validation of the entire GMP manufacturing chain for NFL-102, from extract production through to the lyophilized finished drug product Confirmation of NFL Biosciences' industrial capacity...
► Artikel lesen
01.06.NFL Biosciences Releases New Results on NFL-101 and Reaffirms Its Personalized Approach to Smoking Cessation384Identification of a biomarker predictive of efficacy, enabling a personalized approach to smoking cessation with NFL-101 In the target population, efficacy approximately 30% higher than...
► Artikel lesen
25.05.NFL Biosciences Is Strengthening Its Personalized Medicine Approach to Smoking Cessation With a New Patent Application650Personalized medicine approach that could represent a first in smoking cessation Biomarker rooted in NFL-101's immunomodulatory mechanism of action Rigorous analytical validation...
► Artikel lesen
11.05.NFL Biosciences Clarifies the Objectives and Evaluation Criteria for a Predictive Biomarker Associated With NFL-101414Regulatory News: NFL BIOSCIENCES (Euronext Growth Paris FR0014003XT0 ALNFL, a biopharmaceutical company developing innovative botanical drugs for the treatment of addictions, today clarifies...
► Artikel lesen
04.05.NFL Biosciences: International Scientific Community's Interest in NFL-102 for Smoking Cessation Confirmed by the Selection of Its Work at Two Leading Conferences470Regulatory News: NFL BIOSCIENCES (Euronext Growth Paris FR0014003XT0 ALFNL), a biopharmaceutical company developing innovative botanical drugs for the treatment of addictions, announces that...
► Artikel lesen
15.04.NFL Biosciences Presents Its 2025 Annual Results and Provides an Update on Its Clinical Progress Driven by a New Paradigm in Smoking Cessation616Emergence of a new paradigm in smoking cessation, based on an in-depth understanding of the biological mechanisms of addiction, with the ambition to achieve superior efficacy compared with current...
► Artikel lesen
15.04.NFL Biosciences Strengthens Its Cash Position by €2.6 Million Through Bond Financing Subscribed by a Group of European Institutional Investors675A €2.6 million bond financing has been secured with a group of European investors including Vester Finance, a shareholder of the Company Cash runway is immediately extended until the third...
► Artikel lesen
07.04.A New Paradigm in Tobacco and Nicotine Addiction: NFL Biosciences Demonstrates the Mechanism of Action of NFL-102 in a Video443A breakthrough mechanism of action targeting neural plasticity associated with addiction, particularly through the CREB regulator, a key factor in relapse An educational video illustrating...
► Artikel lesen
11.03.Bpifrance Renews Its Confidence in NFL Biosciences Through the Granting of a €500,000 Loan 648€500,000 loan with a 36-month repayment deferral Financial support to prepare the submission of the Phase 2 clinical trial application for NFL-102 expected in mid-2026 Strengthening...
► Artikel lesen
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1